24 February 2021
Clover Biopharmaceuticals has completed an oversubscribed $230m Series C financing, bringing its total capital raised to $400m in the past year. The proceeds will support the development and expansion of Clover’s protein-based vaccines and biologic cancer therapies. Clover is hoping to initiate a Phase II/III study of its Covid-19 vaccine, SCB-2019, in the first half of 2021.
Independent analysis carried out in the UK shows that the Pfizer/BioNTech vaccine is highly effective against Covid-19, including symptomatic disease, after the first dose. Early data from Public Health England’s SIREN study revealed promising impact in healthcare workers aged below 65. Data further revealed that one dose of the vaccine could reduce the risk of contracting Covid-19 by more than 70%, which rose to 85% after the second dose.
TerSera Therapeutics announced that its intravenous drug cetirizine has been recommended by the US Centres for Disease Control and Prevention (CDC) as an adjunctive therapy to manage anaphylaxis after Covid-19 vaccination in adults.
RedHill is looking to expand its global Phase II/III study of its drug opaganib in severe Covid-19 patients to the US. This will come after the US Food and Drug Administration (FDA) has reviewed the data from the US Phase II study of Opaganib.